DPYD
Dihydropyrimidine dehydrogenase [NADP
As of the edition of 20 October 2026, DPYD (dihydropyrimidine dehydrogenase [NADP, UniProt Q12882) has 4 drugs tested at it and 3 companies on the list, 1 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q12882
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Disease areas
- Cancer; Digestive system; Skin and connective tissue; Hormones; Mouth and teeth; Chemically induced; Ear, nose and throat; Lungs and airways
- Registered trials of its drugs
- 63
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Gimeracil | Marketed | Phase 3 | none listed |
| Eniluracil | Went quiet | Phase 3 | none listed |
| ADH300004 | Stopped | Phase 2 | none listed |
| TAS-114 | Went quiet | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Fennec Pharmaceuticals | Route A |
| Nordic | Route B |
| Taiho | Route B |
The other 0 companies at DPYD
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at DPYD, ranked, with the facts behind eachRequest access. Nothing is shown until you do.